Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
Author:
Funder
F. Hoffmann-La Roche Ltd
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference29 articles.
1. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells;Nahta;Cancer Res,2004
2. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models;Scheuer;Cancer Res,2009
3. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2013
4. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer;Baselga;N Engl J Med,2012
5. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015
Cited by 172 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer;BMC Cancer;2024-01-25
2. Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain;Frontiers in Cardiovascular Medicine;2024-01-19
3. Neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2-positive early or locally advanced breast cancer;Medical alphabet;2024-01-17
4. Efficacy and prognosis of different chemotherapy frameworks in neoadjuvant treatment for HER2-positive breast cancer under targeted therapy:a real-world retrospective observational study;2024-01-05
5. Cardiotoxicity of Agents Used in Patients With Breast Cancer;JCO Oncology Practice;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3